Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital

Bithika Thompson, Mary Korytkowski, David C. Klonoff, Curtiss B. Cook

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


In May 2017, the Diabetes Technology Society convened a panel of US experts on inpatient diabetes management to discuss the current and potential role of continuous subcutaneous insulin infusion (CSII) therapy in the hospital. The panel (1) discussed evidence for current use of CSII in the hospital, (2) recommended contraindications for use in the hospital, and (3) recommended guidelines to maximize chances for safe use of CSII in the hospital. Panel members agreed that larger, prospective, randomized studies are needed to evaluate safety and efficacy of CSII use in the hospital. As CSII technology becomes more complex and its use increases, it is imperative that institutional protocols be in place to ensure safe use of this technology and safe transitions across care areas. Providers need to be cognizant that not all patients currently using CSII as an outpatient are appropriate candidates for continued use in the hospital. This consensus statement provides guidelines for practitioners who may encounter patients using this technology in the inpatient setting.

Original languageEnglish (US)
Pages (from-to)880-889
Number of pages10
JournalJournal of Diabetes Science and Technology
Issue number4
StatePublished - Jul 1 2018


  • continuous subcutaneous insulin infusion (CSII)
  • glucose
  • hospital
  • inpatient
  • insulin pump

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Biomedical Engineering


Dive into the research topics of 'Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital'. Together they form a unique fingerprint.

Cite this